ERDRP-0519 inhibits feline coronavirus in vitro

被引：7

作者：

Camero, Michele ^{[1
]}

Lanave, Gianvito ^{[1
]}

Catella, Cristiana ^{[1
]}

Lucente, Maria Stella ^{[1
]}

Sposato, Alessio ^{[1
]}

Mari, Viviana ^{[1
]}

Tempesta, Maria ^{[1
]}

Martella, Vito ^{[1
]}

Buonavoglia, Alessio ^{[2
]}

机构：

[1] Univ Bari, Dept Vet Med, Valenzano, Italy

[2] Freelance, Bari, Italy

来源：

BMC VETERINARY RESEARCH | 2022年 / 18卷 / 01期

关键词：

Feline coronavirus (FCoV); Feline infectious peritonitis (FIP); Cat; Antiviral; ERDRP-0519; DEPENDENT RNA-POLYMERASES; VIRUS; VACCINATION; INFECTION; SURVIVAL; DISEASE; PROTEIN;

D O I：

10.1186/s12917-022-03153-3

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

Background Coronaviruses (CoVs) are major human and animal pathogens and antiviral drugs are pursued as a complementary strategy, chiefly if vaccines are not available. Feline infectious peritonitis (FIP) is a fatal systemic disease of felids caused by FIP virus (FIPV), a virulent pathotype of feline enteric coronavirus (FeCoV). Some antiviral drugs active on FIPV have been identified, but they are not available in veterinary medicine. ERDRP-0519 (ERDRP) is a non-nucleoside inhibitor, targeting viral RNA polymerase, effective against morbilliviruses in vitro and in vivo. Results The antiviral efficacy of ERDRP against a type II FIPV was evaluated in vitro in Crandell Reese Feline Kidney (CRFK) cells. ERDRP significantly inhibited replication of FIPV in a dose-dependent manner. Viral infectivity was decreased by up to 3.00 logarithms in cell cultures whilst viral load, estimated by quantification of nucleic acids, was reduced by nearly 3.11 logaritms. Conclusions These findings confirm that ERDRP is highly effective against a CoV. Experiments will be necessary to assess whether ERDRP is suitable for treatment of FIPV in vivo.

引用

页数：8

共 44 条

[1] Feline leucocyte antigen class II polymorphism and susceptibility to feline infectious peritonitis [J].